MEP8209A - Modified factor viii - Google Patents

Modified factor viii

Info

Publication number
MEP8209A
MEP8209A MEP-82/09A MEP8209A MEP8209A ME P8209 A MEP8209 A ME P8209A ME P8209 A MEP8209 A ME P8209A ME P8209 A MEP8209 A ME P8209A
Authority
ME
Montenegro
Prior art keywords
factor viii
modified factor
modified
hemophilia
deprived
Prior art date
Application number
MEP-82/09A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
John S Lollar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MEP8209A publication Critical patent/MEP8209A/xx
Publication of ME00601B publication Critical patent/ME00601B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides
MEP-2009-82A 2000-03-10 2001-02-16 Modified factor viii ME00601B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (2)

Publication Number Publication Date
MEP8209A true MEP8209A (en) 2011-12-20
ME00601B ME00601B (me) 2011-12-20

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-82A ME00601B (me) 2000-03-10 2001-02-16 Modified factor viii

Country Status (36)

Country Link
US (3) US6458563B1 (de)
EP (1) EP1280540B1 (de)
JP (1) JP4044337B2 (de)
KR (1) KR100485525B1 (de)
CN (1) CN1191360C (de)
AT (1) ATE391512T1 (de)
AU (2) AU2001238416B2 (de)
BE (1) BE2016C024I2 (de)
BR (2) BRPI0109131B8 (de)
CA (1) CA2400295C (de)
CY (2) CY1108179T1 (de)
CZ (1) CZ298250B6 (de)
DE (1) DE60133541T2 (de)
DK (1) DK1280540T3 (de)
EE (1) EE05075B1 (de)
ES (1) ES2304379T3 (de)
FR (1) FR16C0016I2 (de)
HK (1) HK1051004A1 (de)
HU (2) HU227804B1 (de)
IL (2) IL151371A0 (de)
LT (1) LTC1280540I2 (de)
LU (1) LU93049I2 (de)
ME (1) ME00601B (de)
MX (1) MXPA02008798A (de)
NL (1) NL300808I2 (de)
NO (2) NO331935B1 (de)
NZ (1) NZ520799A (de)
PL (1) PL202936B1 (de)
PT (1) PT1280540E (de)
RS (1) RS50364B (de)
RU (1) RU2285724C2 (de)
SI (1) SI1280540T1 (de)
SK (1) SK286205B6 (de)
UA (1) UA75064C2 (de)
WO (1) WO2001068109A1 (de)
ZA (1) ZA200206810B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US7615622B2 (en) * 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002337901B2 (en) 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
EP1456235A4 (de) * 2001-11-30 2005-08-17 Univ Emory Varianten der c2-domäne des faktors viii
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4644663B2 (ja) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
WO2005000891A2 (en) * 2003-06-26 2005-01-06 Merck Patent Gmbh Thrombopoietin proteins with improved properties
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1699469B1 (de) * 2003-12-03 2010-04-07 University of Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
PL1750733T3 (pl) * 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
RU2423380C2 (ru) * 2004-11-12 2011-07-10 БАЙЕР ХЕЛСКЕА ЛЛСи Сайт-направленная модификация fviii
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090215025A1 (en) 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (de) * 2006-12-22 2008-06-25 CSL Behring GmbH Veränderte Koagulationsfaktoren mit verlängerter in vivo Halbwertzeit
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (de) * 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
US8183345B2 (en) 2007-11-01 2012-05-22 University Of Rochester Recombinant factor VIII having reduced inactivation by activated protein C
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
PL2440239T3 (pl) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Kompozycje hemoglobiny
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
US9050318B2 (en) 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
EP2524054A2 (de) * 2010-01-14 2012-11-21 Haplomics, Inc. Vorhersage und reduktion der alloimmunogenität von proteintherapeutika
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
EP2591099B1 (de) 2010-07-09 2020-11-18 Bioverativ Therapeutics Inc. Chimäre gerinnungsfaktoren
AU2011323236B2 (en) * 2010-11-05 2017-03-30 Takeda Pharmaceutical Company Limited A new variant of antihemophilic factor VIII having increased specific activity
MX2013007551A (es) * 2011-01-05 2013-10-30 Expression Therapeutics Llc Metodo y sistema para suspension de cultivo celular.
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
TWI764092B (zh) 2011-07-08 2022-05-11 美商百歐維拉提夫治療公司 因子viii嵌合及雜交多肽，及其使用方法
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
US10221455B2 (en) 2012-01-12 2019-03-05 Bioverativ Therapeutics Inc. Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
SI2804623T1 (sl) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc. Himerni polipeptidi faktorja VIII in njihove uporabe
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
EP2666782A1 (de) * 2012-05-22 2013-11-27 Imnate Sarl Gerinnungsfaktor VII mit reduzierter Immunogenität
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP3693000B1 (de) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Prokoagulatorische verbindungen
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
EP2877202A4 (de) 2012-07-25 2016-06-01 Biogen Ma Inc Blutfaktorüberwachungstest und verwendungen davon
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (de) 2012-10-30 2016-04-20 Biogen Ma Inc Verfahren zur verwendung von fviii-polypeptid
BR112015013311A2 (pt) 2012-12-07 2017-11-14 Haplomics Inc indução de tolerancia e reparação de mutação do fator 8
US10370431B2 (en) 2013-02-15 2019-08-06 Bioverativ Therapeutics Inc. Optimized factor VIII gene
TWI690325B (zh) 2013-03-15 2020-04-11 美商百歐維拉提夫治療公司 因子viii多肽調配物
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
BR112016009064A2 (pt) 2013-10-22 2017-09-19 Inst Nat Sante Rech Med Dispositivo de emplastro cutâneo; sistema de liberação de fármaco; kit; e método de tratamento da hemofilia em um indivíduo em necessidade do mesmo
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
EP4332839A2 (de) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Pharmakokinetische werkzeuge für populationen und verwendungen davon
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
IL246476B (en) 2014-01-10 2022-06-01 Biogen Ma Inc Factor viii chimeric proteins and their uses
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
US20170051041A1 (en) * 2014-02-19 2017-02-23 Kathleen Pratt Factor viii b cell epitope variants having reduced immunogenicity
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
IL305526A (en) 2015-11-13 2023-10-01 Takeda Pharmaceuticals Co Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy in hemophilia A
KR102404550B1 (ko) 2015-11-13 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
US20190381149A1 (en) 2016-12-02 2019-12-19 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3622065A1 (de) 2017-05-09 2020-03-18 Emory University Gerinnungsfaktorvarianten und ihre verwendung
CN111247251A (zh) 2017-08-09 2020-06-05 比奥维拉迪维治疗股份有限公司 核酸分子及其用途
BR112020015228A2 (pt) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. Uso de vetores lentivirais que expressam fator viii
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
MX2021000582A (es) 2018-07-16 2021-04-12 Baxalta Inc Terapia genica de hemofilia a mediante el uso de vectores virales que codifican variantes del factor viii (fviii) recombinantes con mayor expresion.
SG11202101157VA (en) 2018-08-09 2021-03-30 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
EP3986481A2 (de) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Verfahren zur behandlung mit einer auf viren basierenden gentherapie
JP2023506171A (ja) 2019-12-12 2023-02-15 武田薬品工業株式会社 発現が上昇した組換えｆｖｉｉｉバリアントをコードするウイルスベクターを使用する、血友病ａの遺伝子療法
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
JP2024514307A (ja) * 2021-03-31 2024-04-01 ヘモネティクス・コーポレーション 血液凝固測定装置の品質管理配合物
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
CA3229323A1 (en) 2021-08-23 2023-03-02 Ajay MAGHODIA Optimized factor viii genes
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (de) 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
CA1341174C (en) * 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1456235A4 (de) * 2001-11-30 2005-08-17 Univ Emory Varianten der c2-domäne des faktors viii
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
NO2016007I1 (no) 2016-05-10
BR122013026957A8 (pt) 2017-02-21
EP1280540A1 (de) 2003-02-05
DK1280540T3 (da) 2008-07-14
FR16C0016I1 (de) 2016-04-29
ATE391512T1 (de) 2008-04-15
CA2400295C (en) 2012-01-10
PT1280540E (pt) 2008-06-09
PL359672A1 (en) 2004-09-06
CZ298250B6 (cs) 2007-08-01
CY1108179T1 (el) 2014-02-12
CN1191360C (zh) 2005-03-02
LTC1280540I2 (lt) 2020-05-25
KR20020081426A (ko) 2002-10-26
MXPA02008798A (es) 2003-04-25
RU2002124123A (ru) 2004-03-27
KR100485525B1 (ko) 2005-04-28
NO2016007I2 (no) 2016-05-10
BR122013026957A2 (de) 2004-12-07
AU3841601A (en) 2001-09-24
US20030068785A1 (en) 2003-04-10
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
BRPI0109131B8 (pt) 2021-07-06
EP1280540A4 (de) 2004-11-03
CY2016011I1 (el) 2016-10-05
CZ20023346A3 (cs) 2003-01-15
BR0109131A (pt) 2004-12-07
NZ520799A (en) 2004-06-25
CA2400295A1 (en) 2001-09-20
IL151371A (en) 2010-12-30
US7122634B2 (en) 2006-10-17
JP4044337B2 (ja) 2008-02-06
PL202936B1 (pl) 2009-08-31
HUP0300586A3 (en) 2006-11-28
DE60133541D1 (de) 2008-05-21
US6458563B1 (en) 2002-10-01
ES2304379T3 (es) 2008-10-16
RS50364B (sr) 2009-11-10
US7012132B2 (en) 2006-03-14
SI1280540T1 (sl) 2008-08-31
LU93049I2 (fr) 2016-06-27
NO331935B1 (no) 2012-05-07
BRPI0109131B1 (pt) 2020-08-25
IL151371A0 (en) 2003-04-10
FR16C0016I2 (fr) 2018-11-02
EE200200510A (et) 2004-02-16
CY2016011I2 (el) 2016-10-05
NO20024296L (no) 2002-11-08
CN1416348A (zh) 2003-05-07
YU68002A (sh) 2005-11-28
SK14392002A3 (sk) 2003-06-03
HUP0300586A2 (hu) 2003-06-28
EE05075B1 (et) 2008-10-15
HU227804B1 (en) 2012-03-28
NL300808I2 (nl) 2020-12-21
WO2001068109A1 (en) 2001-09-20
NL300808I1 (de) 2016-05-18
UA75064C2 (en) 2006-03-15
HK1051004A1 (en) 2003-07-18
EP1280540B1 (de) 2008-04-09
BE2016C024I2 (de) 2020-01-30
SK286205B6 (sk) 2008-05-06
JP2003526358A (ja) 2003-09-09
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
AU2001238416B2 (en) 2004-09-02
ME00601B (me) 2011-12-20
HUS1600020I1 (hu) 2016-06-28
DE60133541T2 (de) 2009-05-07

Similar Documents

Publication Publication Date Title
MEP8209A (en) Modified factor viii
ATE340844T1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
DE60204217D1 (de) Verwendung von bioglas
MEP32008A (en) Specific binding agents of human angiopoietin-2
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
NO20061736L (no) Krystallform av epotilon B
ME00671B (me) Nova farmaceutska smeša
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
ES2177316T3 (es) Anticuerpos humanos antifacotores ix/ixa.
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE602004017332D1 (de) Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten
DE50009838D1 (de) Humanes antibiotisches protein
TR200200278T2 (tr) Kalsilitik bileşimler
BR0111785A (pt) Composições e métodos para tratamento de candidìase
WO2002004521A3 (en) Proteins with integrin-like activity
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
ATE321528T1 (de) Verwendung von dattelkern-extrakt zur minderung der anzeichen der hautalterung
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
ATE390144T1 (de) Behandlung von fibrosen